Rebecca Arden Harris
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rebecca Arden Harris has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
David S. Mandell
10 shared publicationsJudith A. Long
Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, PA USA
5 shared publicationsYuhua Bao
4 shared publicationsHenry R. Kranzler
3 shared publicationsRobert Gross
Departments of Medicine and Epidemiology, Biostatistics, Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia
3 shared publicationsHillary R. Bogner
Department of Family Medicine and Community Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA
2 shared publications
Latest Publications
- Open Access
- 4 August 2026
- Published by Elsevier in American Journal of Preventive Cardiology
- Vol. 30
The coverage gap in PREVENT: Why cardiovascular risk prediction needs a lab-free complement
- 4 August 2026
- Published by Elsevier in American Journal of Preventive Cardiology
- Vol. 30
Open AccessThe coverage gap in PREVENT: Why cardiovascular risk prediction needs a lab-free complement
- Open Access
- 29 July 2026
- Published by Elsevier in SSRN Electronic Journal
Back to Bernoulli: A Child-Centred Analysis of Smallpox Inoculation and Ethical Communication
In 1760, Daniel Bernoulli estimated universal smallpox inoculation would increase life expectancy by three years. Jean d'Alembert objected that aggregating gains across a lifespan obscured a fundamental asymmetry: immediate procedural risk versus distant, uncertain benefits decades later. He concluded probability theory could not legitimately compare such temporally mismatched quantities. We demonstrate that d'Alembert's objection is resolved not by abandoning probabilistic analysis but by selecting outcome measures that align the temporal structure of risk and benefit. Reformulating Bernoulli's model within a time-bounded framework (ages 0-15) using discrete-time survival analysis with age-specific mortality parameters reconstructed from eighteenth-century London sources, we estimate inoculation increased childhood survival from 51% to 64% (number needed to inoculate = 8). This demonstrates how metric choice encodes ethical assumptions about whose interests count and over what time horizon, with implications for transparent risk communication in public health interventions.
- 29 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessBack to Bernoulli: A Child-Centred Analysis of Smallpox Inoculation and Ethical Communication
In 1760, Daniel Bernoulli estimated universal smallpox inoculation would increase life expectancy by three years. Jean d'Alembert objected that aggregating gains across a lifespan obscured a fundamental asymmetry: immediate procedural risk versus distant, uncertain benefits decades later. He concluded probability theory could not legitimately compare such temporally mismatched quantities. We demonstrate that d'Alembert's objection is resolved not by abandoning probabilistic analysis but by selecting outcome measures that align the temporal structure of risk and benefit. Reformulating Bernoulli's model within a time-bounded framework (ages 0-15) using discrete-time survival analysis with age-specific mortality parameters reconstructed from eighteenth-century London sources, we estimate inoculation increased childhood survival from 51% to 64% (number needed to inoculate = 8). This demonstrates how metric choice encodes ethical assumptions about whose interests count and over what time horizon, with implications for transparent risk communication in public health interventions.
- Open Access
- 22 June 2026
- Published by Elsevier in Drug and Alcohol Dependence Reports
- Vol. 20, 100459
Three-year cardiovascular risk prediction among people who use cocaine or methamphetamine
- 22 June 2026
- Published by Elsevier in Drug and Alcohol Dependence Reports
- Vol. 20, 100459
Open AccessThree-year cardiovascular risk prediction among people who use cocaine or methamphetamine
- Open Access
- 20 June 2026
- Published by Elsevier in American Journal of Preventive Cardiology
- Vol. 30
Heterogeneous competing causes of death and transportability of the PREVENT equations
- 20 June 2026
- Published by Elsevier in American Journal of Preventive Cardiology
- Vol. 30
Open AccessHeterogeneous competing causes of death and transportability of the PREVENT equations
- Open Access
- 23 June 2025
- Published by Elsevier in American Journal of Preventive Cardiology
- Vol. 23, 101050
Cardiometabolic deaths in premenopausal black and white women
- 23 June 2025
- Published by Elsevier in American Journal of Preventive Cardiology
- Vol. 23, 101050
Open AccessCardiometabolic deaths in premenopausal black and white women
- Open Access
- 24 April 2025
- Published by Elsevier in Drug and Alcohol Dependence Reports
- Vol. 15
Methadone-involved overdose deaths in urban and rural communities before and after the public health emergency flexibilities for methadone take-home doses
- 24 April 2025
- Published by Elsevier in Drug and Alcohol Dependence Reports
- Vol. 15
Open AccessMethadone-involved overdose deaths in urban and rural communities before and after the public health emergency flexibilities for methadone take-home doses
- Open Access
- 1 March 2025
- Published by SAGE Publications in Substance Use: Research and Treatment
- Vol. 19
Stimulant-Involved Cardiovascular Disease Mortality and Life Years Lost, 2014 to 2023
Background: Cocaine and methamphetamine, highly cardiotoxic stimulants, are associated with increased risks of hypertension, coronary artery disease, arrhythmias, cardiomyopathy, and stroke. Objectives: This study examines trends in stimulant-involved cardiovascular disease (CVD) mortality in the U.S. from 2014 to 2023, analyzing CVD subtypes, stimulant type, population characteristics, and years of life lost (YLL). Design: Trend analysis of age-adjusted mortality rates using serial cross-section mortality data from 2014 to 2023. Methods: Using National Vital Statistics System data, we analyzed age-adjusted mortality rates (AAMRs) where CVD was the underlying cause of death and stimulants were contributing factors. We used Joinpoint regression to estimate average annual percent change (AAPC) and compare trends across groups. We calculated YLL based on age at death and demographic-specific life expectancies. Results: From 2014 to 2023, stimulant-involved CVD mortality rose sharply (AAPC: 10.1%), contrasting with stable rates of overall CVD mortality (AAPC: 0.2%). Methamphetamine-involved deaths increased faster (AAPC: 13.8%) than cocaine-involved deaths (AAPC: 6.5%). Among CVD subtypes, cerebrovascular disease showed the steepest rise (AAPC: 15.9%), followed by hypertensive (12.1%) and ischemic heart diseases (7.9%). Older adults (⩾65 years) exhibited the most pronounced increase in stimulant-involved CVD mortality (AAPC: 20.2%), while non-Hispanic American Indian/Alaska Native populations experienced the highest AAPC among racial/ethnic groups (18.1%). Stimulant-involved CVD caused nearly 1 million years of YLL, predominantly among middle-aged males (687 430 YLL) and non-Hispanic White individuals (511 120 YLL). Methamphetamine involvement (580 570 YLL) exceeded that of cocaine (423 528 YLL). Within CVD types, ischemic heart disease was the leading cause (406 248 YLL). Conclusions: Stimulant-involved CVD mortality has surged, especially among non-Hispanic American Indian/Alaska Native and non-Hispanic White populations and older adults, with cerebrovascular disease showing the largest increase among CVD subtypes. The findings reveal the importance of targeted prevention, screening, and intervention.
- 1 March 2025
- Published by SAGE Publications in Substance Use: Research and Treatment
- Vol. 19
Open AccessStimulant-Involved Cardiovascular Disease Mortality and Life Years Lost, 2014 to 2023
Background: Cocaine and methamphetamine, highly cardiotoxic stimulants, are associated with increased risks of hypertension, coronary artery disease, arrhythmias, cardiomyopathy, and stroke. Objectives: This study examines trends in stimulant-involved cardiovascular disease (CVD) mortality in the U.S. from 2014 to 2023, analyzing CVD subtypes, stimulant type, population characteristics, and years of life lost (YLL). Design: Trend analysis of age-adjusted mortality rates using serial cross-section mortality data from 2014 to 2023. Methods: Using National Vital Statistics System data, we analyzed age-adjusted mortality rates (AAMRs) where CVD was the underlying cause of death and stimulants were contributing factors. We used Joinpoint regression to estimate average annual percent change (AAPC) and compare trends across groups. We calculated YLL based on age at death and demographic-specific life expectancies. Results: From 2014 to 2023, stimulant-involved CVD mortality rose sharply (AAPC: 10.1%), contrasting with stable rates of overall CVD mortality (AAPC: 0.2%). Methamphetamine-involved deaths increased faster (AAPC: 13.8%) than cocaine-involved deaths (AAPC: 6.5%). Among CVD subtypes, cerebrovascular disease showed the steepest rise (AAPC: 15.9%), followed by hypertensive (12.1%) and ischemic heart diseases (7.9%). Older adults (⩾65 years) exhibited the most pronounced increase in stimulant-involved CVD mortality (AAPC: 20.2%), while non-Hispanic American Indian/Alaska Native populations experienced the highest AAPC among racial/ethnic groups (18.1%). Stimulant-involved CVD caused nearly 1 million years of YLL, predominantly among middle-aged males (687 430 YLL) and non-Hispanic White individuals (511 120 YLL). Methamphetamine involvement (580 570 YLL) exceeded that of cocaine (423 528 YLL). Within CVD types, ischemic heart disease was the leading cause (406 248 YLL). Conclusions: Stimulant-involved CVD mortality has surged, especially among non-Hispanic American Indian/Alaska Native and non-Hispanic White populations and older adults, with cerebrovascular disease showing the largest increase among CVD subtypes. The findings reveal the importance of targeted prevention, screening, and intervention.
- Open Access
- 19 December 2024
- Published by Springer Nature in Addiction Science & Clinical Practice
- Vol. 19 (1) , 1-10
Organization of primary care and early MOUD discontinuation
Primary care clinic structures and operations may influence early MOUD discontinuation. Flexible scheduling can improve early MOUD retention but must be balanced with clinic efficiency. Multidisciplinary teams can improve retention but require additional resources. Addressing comorbid pain and polydrug use early in the treatment process can help prevent MOUD discontinuation.
- 19 December 2024
- Published by Springer Nature in Addiction Science & Clinical Practice
- Vol. 19 (1) , 1-10
Open AccessOrganization of primary care and early MOUD discontinuation
Primary care clinic structures and operations may influence early MOUD discontinuation. Flexible scheduling can improve early MOUD retention but must be balanced with clinic efficiency. Multidisciplinary teams can improve retention but require additional resources. Addressing comorbid pain and polydrug use early in the treatment process can help prevent MOUD discontinuation.
- 26 July 2024
- Published by Elsevier in Journal of Adolescent Health
- Vol. 75 (6) , 965-968
Trapped in Violence: A Life Table Analysis of Firearm Injury and Death Among Adolescent Black Males
- 26 July 2024
- Published by Elsevier in Journal of Adolescent Health
- Vol. 75 (6) , 965-968
Trapped in Violence: A Life Table Analysis of Firearm Injury and Death Among Adolescent Black Males
- Open Access
- 1 January 2024
- Published by SAGE Publications in Substance Use: Research and Treatment
- Vol. 18
Methadone Take-Home Policies and Associated Mortality: Permitting versus Non-Permitting States
To mitigate COVID-19 exposure risks in methadone clinics, the Substance Abuse and Mental Health Services Administration (SAMHSA) issued a temporary modification of regulations in March 2020 to permit, with state concurrence, extended take-home methadone doses. The modification allowed for up to 28 days of take-home methadone for stable patients and 14 days for those less stable. Using both interrupted time series and difference-in-differences methods, this study examined the association between the policy change and fatal methadone overdoses, comparing states that permitted the expansion of take-home doses with states that did not. The findings suggest the pandemic emergency take-home policy did not increase methadone-involved mortality.
- 1 January 2024
- Published by SAGE Publications in Substance Use: Research and Treatment
- Vol. 18
Open AccessMethadone Take-Home Policies and Associated Mortality: Permitting versus Non-Permitting States
To mitigate COVID-19 exposure risks in methadone clinics, the Substance Abuse and Mental Health Services Administration (SAMHSA) issued a temporary modification of regulations in March 2020 to permit, with state concurrence, extended take-home methadone doses. The modification allowed for up to 28 days of take-home methadone for stable patients and 14 days for those less stable. Using both interrupted time series and difference-in-differences methods, this study examined the association between the policy change and fatal methadone overdoses, comparing states that permitted the expansion of take-home doses with states that did not. The findings suggest the pandemic emergency take-home policy did not increase methadone-involved mortality.